Marjolaine Gauthier-Loiselle

Education

Ph.D., economics, Princeton University; M.S., economics, and B.S., economics and mathematics, University of Montreal

Summary of Experience

Dr. Gauthier-Loiselle specializes in health economics and outcomes research (HEOR). She has conducted research on several diseases and in therapeutic areas such as neuropsychiatry, oncology, nephrology, endocrinology, cardiology, infectious diseases, and rare and hereditary diseases. Dr. Gauthier-Loiselle has extensive experience conducting quantitative research using data from a variety of sources, including health insurance claims, electronic medical records, large national surveys, and clinical trials. Her work includes patient and physician surveys, chart review studies, economic burden studies, treatment pattern studies, safety profile studies, and predictive risk modeling. Dr. Gauthier-Loiselle has served as a peer reviewer for a number of publications, and has published research in several peer-reviewed journals such as the Journal of the American Academy of Dermatology, the Journal of Alzheimer’s Disease, and Cardiovascular Diabetology. Her research has been presented at numerous international clinical conferences. Dr. Gauthier-Loiselle is a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

En Français

• Economic Burden of Illness among Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disorders (CTD)

  Pulmonary Circulation, 2023
  2023

  Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, Liu S, Cloutier M, Lefebvre P

  HEOR, Epidemiology & Market Access
• Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD

  Current Medical Research and Opinion, 2022
  2022

  Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A

  HEOR, Epidemiology & Market Access
• Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey

  Kidney Medicine, 2022
  2022

  Michalopoulos SN, Gauthier-Loiselle M, Aigbogun MS, Serra E, Bungay R, Clynes D, Cloutier M, Kahle E, Guérin A, Farag YMK, Wish JB

  HEOR, Epidemiology & Market Access
• Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data

  Current Medical Research and Opinion, 2022
  2022

  Gauthier-Loiselle M, Tsang Y, Lefebvre P, Agron P, Royer J, Lynum KB, Bennett L, Panjabi S

  HEOR, Epidemiology & Market Access
• Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study

  Advances in Therapy, 2022
  2022

  Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A

  HEOR, Epidemiology & Market Access
• Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States

  Current Medical Research and Opinion, 2021
  2021

  Willey C, Gauthier-Loiselle M, Cloutier M, Shi S, Maitland J, Stellhorn R, Sanon Aigbogun M

  HEOR, Epidemiology & Market Access
• Mental Health and Health-Related Quality of Life Among Nephrology Nurses: A Survey-Based Cross-Sectional Study

  Nephrology Nursing Journal, 2021
  2021

  Montoya V, Donnini K, Gauthier-Loiselle M, Sanon M, Cloutier M, Maitland J, Guérin A, Dutka P, Pryor L, Thomas-Hawkins C, Voegel A, Hoffmann M, Savin S, Kurzman A, Kear T

  HEOR, Epidemiology & Market Access
• Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective

  Journal of Managed Care & Specialty Pharmacy, 2021
  2021

  Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, Guérin A

  HEOR, Epidemiology & Market Access
• Development and validation of a claims-based model to identify patients at risk of chronic thromboembolic pulmonary hypertension following acute pulmonary embolism

  Current Medical Research and Opinion, 2021
  2021

  Kanwar MK, Cole M, Gauthier-Loiselle M, Manceur AM, Tsang Y, Lefebvre P, Panjabi S, Benza RL

  HEOR, Epidemiology & Market Access
• Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis

  Advances in Therapy, 2021
  2021

  Gauthier-Loiselle M, Cloutier M, Toro W, Patel A, Shi S, Davidson M, Bischof M, LaMarca N, Dabbous O

  HEOR, Epidemiology & Market Access
• The societal economic burden of autosomal dominant polycystic kidney disease in the United States

  BMC Health Services Research
  2020

  Cloutier M, Manceur AM, Guerin A, Aigbogun MS, Oberdhan D, Gauthier-Loiselle M

  HEOR, Epidemiology & Market Access
• Economic burden of spinal muscular atrophy in the United States: a contemporary assessment

  Journal of Medical Economics, 2020
  2020

  Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O

  HEOR, Epidemiology & Market Access
• Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review

  Journal of Alzheimer's Disease, 2020
  2020

  Aigbogun MS, Cloutier M, Gauthier-Loiselle M, Guerin A, Ladouceur M, Baker RA, Grundman M, Duffy RA, Hartry A, Gwin K, Fillit H

  HEOR, Epidemiology & Market Access
• Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study

  Current Medical Research and Opinion, 2019
  2019

  Wysham CH, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Duh MS, Young JB

  HEOR, Epidemiology & Market Access
• The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis

  Journal of Managed Care & Specialty Pharmacy, 2019
  2019

  Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ

  HEOR, Epidemiology & Market Access
• Institutionalization risk and costs associated with agitation in Alzheimer's disease

  Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019
  2019

  Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Aigbogun MS

  HEOR, Epidemiology & Market Access
• Claims-Based Risk Model for First Severe COPD Exacerbation

  American Journal of Managed Care. February 2018;24(2):e45-e53.
  2018

  Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan JFP,  Duh MS 

  HEOR, Epidemiology & Market Access
• Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis

  J Drugs Dermatol. Feb 1 2018;17(2):180-186
  2018

  Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A, Ganguli A

  HEOR, Epidemiology & Market Access
• Assessment of costs associated with adverse events in patients with cancer

  PloS One. 2018;13(4):e0196007
  2018

  Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A

  HEOR, Epidemiology & Market Access
• Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis

  J Drugs Dermatol. Feb 1 2018;17(2):187-194
  2018

  Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guérin A, Ganguli A

  HEOR, Epidemiology & Market Access
• The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study

  Journal of the American Academy of Dermatology. 2018 Jul;79(1):60-68
  2018

  Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, Ganguli A

  HEOR, Epidemiology & Market Access
• Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data

  Cardiovascular Diabetology. Aug 24 2018;17(1):118
  2018

  Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH

  HEOR, Epidemiology & Market Access
• Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting

  Urologic Oncology. 2018 Nov;36(11):500.e1-500.e9
  2018

  Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP

  HEOR, Epidemiology & Market Access
• Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis

  Journal of Drugs in Dermatology, 2018
  2018

  Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A

  HEOR, Epidemiology & Market Access
• Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma

  Leukemia and Lymphoma. May 2018;59(5):1133-1142
  2017

  Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L

  HEOR, Epidemiology & Market Access
• Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting

  Medical Oncology. Aug 10 2017;34(9):160
  2017

  Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS

  HEOR, Epidemiology & Market Access
• Real-world Characteristics and Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy versus Androgen Receptor-targeted Therapy after Failure of First-line And

  Clinical Genitourinary Cancer. 2017 Jun 19. pii: S1558-7673(17)30170-2
  2017

  Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS

  HEOR, Epidemiology & Market Access
• Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice

  SpringerPlus, 2016 03; 5: 395. e-pub ahead of print 2016/04/06
  2016

  Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B

  HEOR, Epidemiology & Market Access
• Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer

  Breast Cancer Research and Treatment, 2016 05; 157(1): 145-156. e-pub ahead of print 2016/04/25
  2016

  Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B

  HEOR, Epidemiology & Market Access

• October 23, 2023

  HEOR and Epidemiology Research from Analysis Group Featured at AMCP Nexus Meeting

  HEOR, Epidemiology & Market Access
• July 19, 2022

  Analysis Group Announces Recent Promotions and Welcomes New Consultants and Affiliates